A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
- DOI
- Language of the publication
- English
- Date
- 2022-10-25
- Type
- Article
- Author(s)
- Tauzin, Alexandra
- Gong, Shang Yu
- Chatterjee, Debashree
- Ding, Shilei
- Painter, Mark M.
- Goel, Rishi R.
- Beaudoin-Bussières, Guillaume
- Marchitto, Lorie
- Boutin, Marianne
- Laumaea, Annemarie
- Okeny, James
- Gendron-Lepage, Gabrielle
- Bourassa, Catherine
- Medjahed, Halima
- Goyette, Guillaume
- Williams, Justine C.
- Bo, Yuxia
- Gokool, Laurie
- Morrisseau, Chantal
- Arlotto, Pascale
- Bazin, Renée
- Fafard, Judith
- Tremblay, Cécile
- Kaufmann, Daniel E.
- De Serres, Gaston
- Richard, Jonathan
- Côté, Marceline
- Duerr, Ralf
- Martel-Laferrière, Valérie
- Greenplate, Allison R.
- Wherry, John E.
- Finzi, Andrés
- Publisher
- Cell Press
Abstract
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals.
Plain language summary
In this study, Tauzin et al. report that the third dose of SARS-CoV-2 mRNA vaccine elicits strong humoral responses against VOCs in naive individuals, regardless of the interval between the first two doses. However, these responses remain lower than those induced by hybrid immunity. HIGHLIGHTS --An extended interval elicits better humoral responses than a short interval --Humoral responses decline after the second dose of mRNA vaccine --A boost elicits similar humoral responses in short- and longinterval recipients --Hybrid immunity leads to stronger and more sustained humoral responses
Subject
- Health
Rights
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Peer review
Yes
Open access level
Gold
Article
- Journal title
- Cell Reports
- Journal volume
- 41
- Article number
- 111554
Citation(s)
1.Tauzin A, Shang Yu Gong, Chatterjee D, et al. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. Cell Reports. 2022;41(4):111554-111554. doi:https://doi.org/10.1016/j.celrep.2022.111554